1-(1-methyl-1H-indol-3-yl)-3-[1-(triphenylmethyl)-1H-imidazol-2-yl]-2-propen-1-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 1-(1-methyl-1H-indol-3-yl)-3-[1-(triphenylmethyl)-1H-imidazol-2-yl]-2-propen-1-one
• 英文别名: (E)-1-(1-methylindol-3-yl)-3-(1-tritylimidazol-2-yl)prop-2-en-1-one
• 化学式: C₃₄H₂₇N₃O
• 分子量: 493.608
• InChiKey: GRRIDYQMJLEUKY-QURGRASLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  39.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(1-甲基-1H-吲哚-3-基)-1-乙酮 、 2-甲酰基-1-三苯甲基-1H-咪唑 在 氢氧化钾 作用下， 以 乙醇 、 氯仿 、 水 为溶剂， 生成 1-(1-methyl-1H-indol-3-yl)-3-[1-(triphenylmethyl)-1H-imidazol-2-yl]-2-propen-1-one
  参考文献：
  名称：

  Ketone derivatives

  摘要：

  本发明涉及通式（I）的酮类：其中R1代表氢原子或从C1-6烷基，C3-6烯基，C3-10炔基，C3-7环烷基，C3-7环烷基C1-4烷基，苯基，苯基C1-3烷基，-CO2R8，-COR8，-CONR8R9或-SO2R8中选择的基团（其中R8和R9可能相同或不同，每个代表氢原子，C1-6烷基或C3-7环烷基，或苯基或苯基C1-4烷基，其中苯基可以选择地被一个或多个C1-4烷基，C1-4烷氧基或羟基或卤素原子取代，但R1代表--CO2R8或--SO2R8基团时，R8不代表氢原子）；R2代表氢原子或C1-6烷基，C3-6烯基，C3-7环烷基，苯基或苯基C1-3烷基；R3和R4可能相同或不同，每个代表氢原子或C1-6烷基；或R2和R3可以一起表示为一个烷基链-(CH2)n-，其中n表示1、2或3；由R5、R6和R7表示的基团中的一个是氢原子或C1-6烷基，C3-7环烷基，C3-6烯基，苯基或苯基C1-3烷基，另外两个基团可能相同或不同，代表氢原子或C1-6烷基；Q代表氢原子或卤素原子或羟基，C1-4烷氧基，苯基C1-3烷氧基或C1-6烷基，或基团-NR10R11或-CONR10R11（其中R10和R11可能相同或不同，每个代表氢原子或C1-4烷基或C3-4烯基，或与它们连接的氮原子一起形成饱和的5到7成员环）；以及其生理上可接受的盐和溶剂。这些化合物是5-HT和5-HT3受体效应的有效选择性拮抗剂，例如在治疗精神疾病、焦虑和恶心和呕吐方面有用。

  公开号：

  US04950681A1

文献信息

• Ketone Derivatives
  申请人：GLAXO GROUP LIMITED

  公开号：EP0307145A1

  公开（公告）日：1989-03-15

  The invention relates to ketones of the general formula (I): wherein R¹ represents a hydrogen atom or a group selected from C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₁₀alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, phenyl, phenylC₁₋₃alkyl, -CO₂R⁸, -COR⁸, -CONR⁸R⁹ or -SO₂R⁸ (wherein R⁸ and R⁹, which may be the same of different, each represents a hydrogen atom, a C₁₋₆alkyl or C₃₋₇cycloalkyl group, or a phenyl or phenylC₁₋₄alkyl group, in which the phenyl group is optionally substituted by one or more C₁₋₄alkyl, C₁₋₄alkoxy or hydroxy groups or halogen atoms, with the proviso that R⁸ does not represent a hydrogen atom when R¹ represents a group -CO₂R⁸ or -SO₂R⁸); R² represents a hydrogen atom or a C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₇cycloalkyl, phenyl or phenylC₁₋₃alkyl group; R³ and R⁴, which may be the same of different, each represents a hydrogen atom or a C₁₋₆alkyl group; or R² and R³ may together represent an alkylene chain -(CH₂)n-, where n represents 1, 2 or 3; one of the groups represented by R⁵, R⁶ and R⁷ is a hydrogen atom or a C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₆alkenyl, phenyl or phenylC₁₋₃alkyl group, and each of the other two groups, which may be be same or different, represents a hydrogen atom or a C₁₋₆alkyl group; Q represents a hydrogen atom or a halogen atom or a hydroxy, C₁₋₄alkoxy, phenylC₁₋₃alkoxy or C₁₋₆alkyl group or a group -NR¹⁰R¹¹ or -CONR¹⁰R¹¹ (wherein R¹⁰ and R¹¹, which may be the same or different, each represents a hydrogen atom or a C₁₋₄alkyl or C₃₋₄alkenyl group, or together with the nitrogen atom to which they are attached form a saturated 5 to 7 membered ring); and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT and 5-HT₃ receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.

  本发明涉及通式(I)的酮： 其中 R¹ 代表氢原子或选自 C₁₋₆烷基、C₃₋₆烯基、C₃₋₁₀ 烷基、C₃₋₇ 环烷基、C₃₋₇ 环烷基、C₁₋₄烷基苯基、C₁₋₃烷基、-CO₂R⁸、-COR⁸、-CONR⁸R⁹或-SO₂R⁸（其中 R⁸ 和 R𠞙 可以相同或不同，各自代表一个氢原子）、C₁₋₆ 烷基或 C₃₋₇ 环烷基，或苯基或苯基 C₁₋₄ 烷基，其中苯基任选被一个或多个 C₁₋₄ 烷基取代、R¹代表-CO₂R⁸或-SO₂R⁸基团时，R⁸不代表氢原子；） R² 代表氢原子或 C₁₋₆烷基、C₃₋₆烯基、C₃₋₇环烷基、苯基或苯基₁₋₃； R³ 和 R⁴（可以相同或不同）各自代表一个氢原子或一个 C₁₋₆ 烷基；或 R² 和 R³ 可共同代表亚烷基链-(CH₂)n-，其中 n 代表 1、2 或 3； R⁵、R⁶ 和 R⁷ 所代表的基团之一是氢原子或 C₁₋₆ 烷基、C₃₋₇ 环烷基、C₃₋₆、 Q 代表氢原子或卤原子或羟基、C₁₋₄烷氧基、苯基C₁₋₃烷氧基或 C₁₋₆烷基或基团 -NR¹⁰R¹¹ 或 -CONR¹⁰R¹¹ (其中 R¹⁰ 和 R¹、可相同或不同，各自代表一个氢原子或一个 C₁₋₄烷基或 C₃₋₄ 烯基，或与所连接的氮原子一起形成一个 5 至 7 个成员的饱和环）； 及其生理上可接受的盐和溶剂。 这些化合物是 5-HT 和 5-HT₃ 受体效应的强效选择性拮抗剂，可用于治疗精神障碍、焦虑、恶心和呕吐等疾病。
• US4950681A
  申请人：——

  公开号：US4950681A

  公开（公告）日：1990-08-21
• Ketone derivatives
  申请人：Glaxo Group Limited

  公开号：US04950681A1

  公开（公告）日：1990-08-21

  The invention relates to ketones of the general formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenylC.sub.1-3 alkyl, --CO.sub.2 R.sup.8, --COR.sup.8, --CONR.sup.8 R.sup.9 or --SO.sub.2 R.sup.8 (wherein R.sup.8 and R.sup.9, which may be the same or different, each represents a hydrogen atom, a C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl group, or a phenyl or phenylC.sub.1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C.sub.1-4 -alkyl, C.sub.1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R.sup.8 does not represent a hydrogen atom when R.sup.1 represents a group --CO.sub.2 R.sup.8 or --SO.sub.2 R.sup.8); R.sup.2 represents a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-7 cycloalkyl, phenyl or phenylC.sub.1-3 alkyl group; R.sup.3 and R.sup.4, which may be the same or different, each represents a hydrogen atom or a C.sub.1-6 alkyl group; or R.sup.2 and R.sup.3 may together represent an alkylene chain -(CH.sub.2).sub.n --, where n represents 1, 2 or 3; one of the groups represented by R.sup.5, R.sup.6 and R.sup.7 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenylC.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group; Q represents a hydrogen atom or a halogen atom or a hydroxy, C.sub.1-4 alkoxy, phenylC.sub.1-3 alkoxy or C.sub.1-6 alkyl group or a group --NR.sup.10 R.sup.11 or --CONR.sup.10 R.sup.11 (wherein R.sup.10 and R.sup.11, which may be the same or different, each represents a hydrogen atom or a C.sub.1-4 alkyl or C.sub.3-4 alkenyl group, or together with the nitrogen atom to which they are attached form a saturated 5 to 7 membered ring); and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT and 5-HT.sub.3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.

  本发明涉及通式（I）的酮类：其中R1代表氢原子或从C1-6烷基，C3-6烯基，C3-10炔基，C3-7环烷基，C3-7环烷基C1-4烷基，苯基，苯基C1-3烷基，-CO2R8，-COR8，-CONR8R9或-SO2R8中选择的基团（其中R8和R9可能相同或不同，每个代表氢原子，C1-6烷基或C3-7环烷基，或苯基或苯基C1-4烷基，其中苯基可以选择地被一个或多个C1-4烷基，C1-4烷氧基或羟基或卤素原子取代，但R1代表--CO2R8或--SO2R8基团时，R8不代表氢原子）；R2代表氢原子或C1-6烷基，C3-6烯基，C3-7环烷基，苯基或苯基C1-3烷基；R3和R4可能相同或不同，每个代表氢原子或C1-6烷基；或R2和R3可以一起表示为一个烷基链-(CH2)n-，其中n表示1、2或3；由R5、R6和R7表示的基团中的一个是氢原子或C1-6烷基，C3-7环烷基，C3-6烯基，苯基或苯基C1-3烷基，另外两个基团可能相同或不同，代表氢原子或C1-6烷基；Q代表氢原子或卤素原子或羟基，C1-4烷氧基，苯基C1-3烷氧基或C1-6烷基，或基团-NR10R11或-CONR10R11（其中R10和R11可能相同或不同，每个代表氢原子或C1-4烷基或C3-4烯基，或与它们连接的氮原子一起形成饱和的5到7成员环）；以及其生理上可接受的盐和溶剂。这些化合物是5-HT和5-HT3受体效应的有效选择性拮抗剂，例如在治疗精神疾病、焦虑和恶心和呕吐方面有用。